Acta Haematol

1. LEVY YURKOVSKI I, Tadmor T
   Approach to hairy-cell leukemia in the new therapeutic era with special emphasis on age and comorbidities.
   Acta Haematol. 2025 Aug 4:1-19. doi: 10.1159/000547722.
   

   >> Share

   
   

   
   Am J Hematol

2. MESTRE-DURAN C, Leon-Triana O, Bareke H, Pertinez L, et al
   Ex Vivo IL-15-Stimulated NK Cells as Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Leukemia.
   Am J Hematol. 2025 Aug 8. doi: 10.1002/ajh.70023.
   

   >> Share

   
   
3. BALL S, Jain AG, Al Ali N, Aguirre LE, et al
   Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (>/= 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia.
   Am J Hematol. 2025 Aug 7. doi: 10.1002/ajh.70031.
   

   >> Share

   
   
4. ZHANG X, Cao Y, Wei J, Zhai W, et al
   Efficacy and Safety of the Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination With Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Refractory/Relapsed D
   Am J Hematol. 2025 Aug 6. doi: 10.1002/ajh.70026.
   

   >> Share

   
   

   
   Ann Hematol

5. KRETSCHMER L, Ruhnke L, Schliemann C, Fransecky L, et al
   VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.
   Ann Hematol. 2025;104:3647-3654.
   

   >> Share

   
   
6. RUBIO MA, Cisa-Wieczorek S, Mozos A, Castellet H, et al
   SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions.
   Ann Hematol. 2025;104:3655-3667.
   

   >> Share

   
   
7. MARAGLINO AME, Sammassimo S, Lolli G, Clemente A, et al
   Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma.
   Ann Hematol. 2025;104:3875-3879.
   

   >> Share

   
   

   
   Blood

8. CHEN S, Xiao Z
   Atypical cytoplasmic inclusions and erythrophagocytosis in acute myeloid leukemia with KMT2A::MLLT3 and U2AF1 mutation.
   Blood. 2025;146:765.
   

   >> Share

   
   
9. ABRUZZESE E, Chelysheva E
   How I Manage Chronic Myeloid Leukemia During Pregnancy.
   Blood. 2025 Aug 4:blood.2024026513. doi: 10.1182/blood.2024026513.
   

   >> Share

   
   

   
   Cancer

10. BURTON H, Boussi L, Nemirovsky D, Derkach A, et al
    Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs.
    Cancer. 2025;131:e70024.
    

    >> Share

    
    
11. SENAPATI J, Kantarjian HM, Kadia TM, Kekedjian J, et al
    Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia.
    Cancer. 2025;131:e70028.
    

    >> Share

    
    

    
    Cancer Lett

12. HU X, Hu T, Cao S, Zheng L, et al
    The ALDH2-PKC delta-SHMT2 axis regulates cellular metabolic plasticity to promote leukemia stem cells self-renewal and evasion of chemotherapy in AML.
    Cancer Lett. 2025 Jul 31:217963. doi: 10.1016/j.canlet.2025.217963.
    

    >> Share

    
    

    
    Eur J Immunol

13. YUE K, Liang S, Wu N, Jia M, et al
    HLA-DR-Expressing gammadelta T Cells Facilitate the Anti-Leukemia Activity of alphabeta T Cells.
    Eur J Immunol. 2025;55:e70025.
    

    >> Share

    
    
14. SANCHEZ-HERRERA J, Valenzuela-Vazquez L, Nunez-Enriquez JC, Arellano-Juvera F, et al
    Influence of SLAM Family Receptors in the NK-Cell-Mediated Surveillance of Lymphoblastic Acute Leukemia.
    Eur J Immunol. 2025;55:e70014.
    

    >> Share

    
    

    
    J Biol Chem

15. ZHANG L, Zhong J, Yang L, Ye Q, et al
    The transcription factor HOXA9 induces expression of the chromatin modifier SMYD3 to drive leukemogenesis.
    J Biol Chem. 2025;301:110320.
    

    >> Share

    
    

    
    J Clin Oncol

16. ZEIDNER JF, Lin TL, Welkie RL, Curran E, et al
    Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
    J Clin Oncol. 2025;43:2606-2615.
    

    >> Share

    
    

    
    J Pediatr Hematol Oncol

17. SAFI Z, Fakhouri M, Monsef C, Assaf N, et al
    The ETV6::NCOA2 Fusion, a Recurrent Cytogenetic Abnormality in Childhood Leukemia With Defining Properties.
    J Pediatr Hematol Oncol. 2025 Aug 6. doi: 10.1097/MPH.0000000000003095.
    

    >> Share

    
    

    
    Leuk Lymphoma

18. PARK H, Lee JH, Lee JH, Park HS, et al
    Effectiveness of prophylactic intrathecal chemotherapy and risk factors of central nervous system relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
    Leuk Lymphoma. 2025 Aug 7:1-11. doi: 10.1080/10428194.2025.2541302.
    

    >> Share

    
    
19. AGRAWAL V, Aldoss I, Pullarkat V
    Extramedullary sites of disease in B-cell acute lymphoblastic leukemia: incidence, biology, and treatment.
    Leuk Lymphoma. 2025 Aug 5:1-12. doi: 10.1080/10428194.2025.2541024.
    

    >> Share

    
    
20. ZIELONKA K, Izdebski B, Drozd-Sokolowska J, Pruszczyk-Matusiak K, et al
    Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group.
    Leuk Lymphoma. 2025 Aug 1:1-9. doi: 10.1080/10428194.2025.2535693.
    

    >> Share

    
    

    
    Leuk Res

21. YANG X, Huang R
    Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapies.
    Leuk Res. 2025;157:107924.
    

    >> Share

    
    

    
    Leukemia

22. SUZUKI K, Kusayanagi S, Kuze Y, Hata M, et al
    Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-beta axis in adult T-cell leukemia/lymphoma.
    Leukemia. 2025 Aug 4. doi: 10.1038/s41375-025-02725.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share